[
  {
    "ts": null,
    "headline": "Stocks Close Higher After Trump Unveils New Tariffs",
    "summary": "U.S. stocks ended higher Friday after a three-day losing streak, showing investors aren’t concerned about the broad impact of new tariffs on drugs, trucks and furniture.",
    "url": "https://finnhub.io/api/news?id=2e7103a4b46ce12e8363a0817076daf0d2e8a329f7bbfc6c7af0a58bdf05dbea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758918660,
      "headline": "Stocks Close Higher After Trump Unveils New Tariffs",
      "id": 136896929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "U.S. stocks ended higher Friday after a three-day losing streak, showing investors aren’t concerned about the broad impact of new tariffs on drugs, trucks and furniture.",
      "url": "https://finnhub.io/api/news?id=2e7103a4b46ce12e8363a0817076daf0d2e8a329f7bbfc6c7af0a58bdf05dbea"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Faces Court Over Depo-Provera Brain Tumor Claims",
    "summary": "Pfizer Inc. (NYSE: PFE) faces mounting legal challenges over claims that its contraceptive injection Depo-Provera (DMPA) is linked to brain tumors, with a key court hearing set for late September that could determine whether affected women can pursue their cases in court. The multidistrict litigation (MDL), consolidated in Florida, was launched on behalf of women who developed intracranial meningiomas after using Depo-Provera. Plaintiffs argue the company failed to provide adequate warnings abou",
    "url": "https://finnhub.io/api/news?id=5b5823d98ec8bbe442ab521ab95ed95a130fd70b682b6c2fbc17d5cd2339ee2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758911216,
      "headline": "Pfizer Faces Court Over Depo-Provera Brain Tumor Claims",
      "id": 136897112,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE: PFE) faces mounting legal challenges over claims that its contraceptive injection Depo-Provera (DMPA) is linked to brain tumors, with a key court hearing set for late September that could determine whether affected women can pursue their cases in court. The multidistrict litigation (MDL), consolidated in Florida, was launched on behalf of women who developed intracranial meningiomas after using Depo-Provera. Plaintiffs argue the company failed to provide adequate warnings abou",
      "url": "https://finnhub.io/api/news?id=5b5823d98ec8bbe442ab521ab95ed95a130fd70b682b6c2fbc17d5cd2339ee2e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.",
    "summary": "Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.",
    "url": "https://finnhub.io/api/news?id=419b097963dfa4a43b4a84cafebb9ef46b0d55a5dafa5472eb05116de58124f3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758905460,
      "headline": "Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.",
      "id": 136921039,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.",
      "url": "https://finnhub.io/api/news?id=419b097963dfa4a43b4a84cafebb9ef46b0d55a5dafa5472eb05116de58124f3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (PFE) Doubles Down on Obesity Market—But Will It Pay Off?",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best value stocks in Goldman Sachs’ portfolio. The company appears to have seized an opportunity that may help it strengthen its portfolio with newer therapies in the face of looming patent expiries for some of its key drugs, which could reduce revenue by $15 billion by the end of this […]",
    "url": "https://finnhub.io/api/news?id=d0bfdf7e5f97d66988965d231ba31ab603f0fb336574247ded2d804cbab5f6f3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758899393,
      "headline": "Pfizer (PFE) Doubles Down on Obesity Market—But Will It Pay Off?",
      "id": 136892834,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the best value stocks in Goldman Sachs’ portfolio. The company appears to have seized an opportunity that may help it strengthen its portfolio with newer therapies in the face of looming patent expiries for some of its key drugs, which could reduce revenue by $15 billion by the end of this […]",
      "url": "https://finnhub.io/api/news?id=d0bfdf7e5f97d66988965d231ba31ab603f0fb336574247ded2d804cbab5f6f3"
    }
  },
  {
    "ts": null,
    "headline": "Trump's new tariffs on pharma, furniture, & trucks: What to know",
    "summary": "President Trump announced sweeping new tariffs on pharmaceuticals, heavy trucks, and furniture imports. The duty on pharmaceuticals sits at 100% for patented drugs unless the producer is building a manufacturing plant in the US. White House columnist for The Hill, Niall Stanage, and Yahoo Finance senior reporter Brooke DiPalma outline the details of the tariff policy and examine the respective market reactions. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=d7991ae95fc41cdc2d33538ff9b6e84b21dd938423a6bbf5b5aea179b58efa25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758895101,
      "headline": "Trump's new tariffs on pharma, furniture, & trucks: What to know",
      "id": 136892599,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "President Trump announced sweeping new tariffs on pharmaceuticals, heavy trucks, and furniture imports. The duty on pharmaceuticals sits at 100% for patented drugs unless the producer is building a manufacturing plant in the US. White House columnist for The Hill, Niall Stanage, and Yahoo Finance senior reporter Brooke DiPalma outline the details of the tariff policy and examine the respective market reactions. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=d7991ae95fc41cdc2d33538ff9b6e84b21dd938423a6bbf5b5aea179b58efa25"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Rise After Trump Unveils New Tariffs",
    "summary": "President Trump unveiled new tariffs on drugs, trucks and furniture.  U.S. stocks rose, putting them on track to break a three-day losing streak.  Trump said the 100% levy would apply only to patented or branded drugs, and to those sold by companies that aren’t building plants in America.",
    "url": "https://finnhub.io/api/news?id=856bff1ba18617b6a487cbab7a346d6f0b0f883984bcb3dc4937968a7dd39772",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758895020,
      "headline": "Stocks Rise After Trump Unveils New Tariffs",
      "id": 136892600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "President Trump unveiled new tariffs on drugs, trucks and furniture.  U.S. stocks rose, putting them on track to break a three-day losing streak.  Trump said the 100% levy would apply only to patented or branded drugs, and to those sold by companies that aren’t building plants in America.",
      "url": "https://finnhub.io/api/news?id=856bff1ba18617b6a487cbab7a346d6f0b0f883984bcb3dc4937968a7dd39772"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Merck, Pfizer Stocks Rise After Trump Unveils Pharma Tariffs",
    "summary": "Big U.S. and European drugmakers largely brushed off President Trump's new pharmaceutical tariffs, though some Asian companies suffered losses.  Trump on Thursday announced a 100% tariff on branded or patented drugs from companies that aren't building plants in America.  Generic drugs are exempt from the levy.",
    "url": "https://finnhub.io/api/news?id=4d27bfd0b6a8bdded47d43f3896fadc309e37c9e690cc4233457e9f6456324dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758894528,
      "headline": "Eli Lilly, Merck, Pfizer Stocks Rise After Trump Unveils Pharma Tariffs",
      "id": 136892602,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Big U.S. and European drugmakers largely brushed off President Trump's new pharmaceutical tariffs, though some Asian companies suffered losses.  Trump on Thursday announced a 100% tariff on branded or patented drugs from companies that aren't building plants in America.  Generic drugs are exempt from the levy.",
      "url": "https://finnhub.io/api/news?id=4d27bfd0b6a8bdded47d43f3896fadc309e37c9e690cc4233457e9f6456324dc"
    }
  },
  {
    "ts": null,
    "headline": "Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit",
    "summary": "Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.",
    "url": "https://finnhub.io/api/news?id=7279f6519b2a590768586751669050dbc70f83812e87aaceb7775a35761c18d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758893040,
      "headline": "Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit",
      "id": 136892605,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.",
      "url": "https://finnhub.io/api/news?id=7279f6519b2a590768586751669050dbc70f83812e87aaceb7775a35761c18d5"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Discusses Sentiment Surrounding Pfizer (PFE)",
    "summary": "We recently published 14 Stocks Jim Cramer Discussed Including His 2 Top Quantum Computing Stocks. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE)’s shares are down by 10% year-to-date. In this appearance, Cramer discussed the firm’s $43 billion acquisition of drug company Seagen. Cramer has commented on the […]",
    "url": "https://finnhub.io/api/news?id=7c4734a1eb33f30097263528e4ae9a9179b016035d19ab208feefe72731e728c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758891347,
      "headline": "Jim Cramer Discusses Sentiment Surrounding Pfizer (PFE)",
      "id": 136892840,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published 14 Stocks Jim Cramer Discussed Including His 2 Top Quantum Computing Stocks. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE)’s shares are down by 10% year-to-date. In this appearance, Cramer discussed the firm’s $43 billion acquisition of drug company Seagen. Cramer has commented on the […]",
      "url": "https://finnhub.io/api/news?id=7c4734a1eb33f30097263528e4ae9a9179b016035d19ab208feefe72731e728c"
    }
  },
  {
    "ts": null,
    "headline": "Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock?",
    "summary": "The pharmaceutical giant is again plunging headfirst into weight-loss drug development.",
    "url": "https://finnhub.io/api/news?id=a156e10d0786be1b2fdd48c3f7b75f8abecbeceefc44c5aba75681b13c01466f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758890700,
      "headline": "Did Pfizer Just Give Investors 7 Billion Reasons to Buy Its Stock?",
      "id": 136892841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The pharmaceutical giant is again plunging headfirst into weight-loss drug development.",
      "url": "https://finnhub.io/api/news?id=a156e10d0786be1b2fdd48c3f7b75f8abecbeceefc44c5aba75681b13c01466f"
    }
  },
  {
    "ts": null,
    "headline": "Trump’s overnight demand for 100% tariffs on pharmaceuticals will be ‘a meaningful commercial hit for U.S. consumers,’ top analyst says",
    "summary": "The good news: There are several loopholes in Trump’s proposal that mean the impact of the new taxes may be limited.",
    "url": "https://finnhub.io/api/news?id=a1b8196a1e904d6a633763c3243a38cdc75112b8f6b4e8f666b058d2cdc24ff3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758885899,
      "headline": "Trump’s overnight demand for 100% tariffs on pharmaceuticals will be ‘a meaningful commercial hit for U.S. consumers,’ top analyst says",
      "id": 136897113,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The good news: There are several loopholes in Trump’s proposal that mean the impact of the new taxes may be limited.",
      "url": "https://finnhub.io/api/news?id=a1b8196a1e904d6a633763c3243a38cdc75112b8f6b4e8f666b058d2cdc24ff3"
    }
  },
  {
    "ts": null,
    "headline": "President Trump's 100% Tariff Threat: What It Means For Your Pharma Portfolio",
    "summary": "Explore how Trump's MFN pricing and 100% drug import tariffs impact pharma stocks.",
    "url": "https://finnhub.io/api/news?id=f87454e5d95e6da200bbd80a0968fd7d3fa1631bf2ee86d435f94ffa5e918741",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758885865,
      "headline": "President Trump's 100% Tariff Threat: What It Means For Your Pharma Portfolio",
      "id": 136892883,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1645808639/image_1645808639.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Explore how Trump's MFN pricing and 100% drug import tariffs impact pharma stocks.",
      "url": "https://finnhub.io/api/news?id=f87454e5d95e6da200bbd80a0968fd7d3fa1631bf2ee86d435f94ffa5e918741"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Passive Income Stocks to Buy Now",
    "summary": "These dividend stocks offer high yields and growth catalysts that could support payouts for decades.",
    "url": "https://finnhub.io/api/news?id=ac55fbbb87f120925f2cecfedab22cb6a1b1b33992e12852f8d54bdddc334b82",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758879900,
      "headline": "2 Top Passive Income Stocks to Buy Now",
      "id": 136892713,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These dividend stocks offer high yields and growth catalysts that could support payouts for decades.",
      "url": "https://finnhub.io/api/news?id=ac55fbbb87f120925f2cecfedab22cb6a1b1b33992e12852f8d54bdddc334b82"
    }
  },
  {
    "ts": null,
    "headline": "Anemia Treatment Market Analysis by Disease Type, Therapy Class, Route of Administration, Countries and Competitive Landscape 2025-2033",
    "summary": "The Global Anemia Treatment Market is projected to grow from USD 11.84 billion in 2024 to USD 22.45 billion by 2033, at a CAGR of 7.37% from 2025 to 2033. Increased awareness and improved treatment measures are driving this growth. Key segments analyzed include iron deficiency anemia, CKD anemia, and treatment modalities like oral supplements and intravenous iron. Technological advancements, such as gene therapy and HIF-PH inhibitors, are enhancing patient outcomes. The market faces challenges i",
    "url": "https://finnhub.io/api/news?id=f4330bce298bfb86ebae593c37a866980e598501e1fe1b38eb621be89495faf0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758878940,
      "headline": "Anemia Treatment Market Analysis by Disease Type, Therapy Class, Route of Administration, Countries and Competitive Landscape 2025-2033",
      "id": 136892843,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Global Anemia Treatment Market is projected to grow from USD 11.84 billion in 2024 to USD 22.45 billion by 2033, at a CAGR of 7.37% from 2025 to 2033. Increased awareness and improved treatment measures are driving this growth. Key segments analyzed include iron deficiency anemia, CKD anemia, and treatment modalities like oral supplements and intravenous iron. Technological advancements, such as gene therapy and HIF-PH inhibitors, are enhancing patient outcomes. The market faces challenges i",
      "url": "https://finnhub.io/api/news?id=f4330bce298bfb86ebae593c37a866980e598501e1fe1b38eb621be89495faf0"
    }
  },
  {
    "ts": null,
    "headline": "US, European pharma stocks steady after Trump's tariff move, Asia slips",
    "summary": "SINGAPORE/SHANGHAI (Reuters) -Shares of U.S. and European pharmaceutical firms were little changed on Friday, while Asian drugmakers declined, after President Donald Trump announced 100% tariffs on branded drugs imported by firms that are not building plants in the U.S.  Analysts said the move was widely expected and unlikely to materially hit the industry, given that most drugmakers have pledged billions of dollars in U.S. manufacturing investments.  The conditions sort of weaken the announcement, which is probably why the market is not overly reacting, said Peter Cardillo, chief market economist at Spartan Capital Securities in New York.",
    "url": "https://finnhub.io/api/news?id=03f3df8ceedc17cdf3d4f87400d2066dff8a84524402fad13e174e3d869cd27f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758855120,
      "headline": "US, European pharma stocks steady after Trump's tariff move, Asia slips",
      "id": 136892746,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "SINGAPORE/SHANGHAI (Reuters) -Shares of U.S. and European pharmaceutical firms were little changed on Friday, while Asian drugmakers declined, after President Donald Trump announced 100% tariffs on branded drugs imported by firms that are not building plants in the U.S.  Analysts said the move was widely expected and unlikely to materially hit the industry, given that most drugmakers have pledged billions of dollars in U.S. manufacturing investments.  The conditions sort of weaken the announcement, which is probably why the market is not overly reacting, said Peter Cardillo, chief market economist at Spartan Capital Securities in New York.",
      "url": "https://finnhub.io/api/news?id=03f3df8ceedc17cdf3d4f87400d2066dff8a84524402fad13e174e3d869cd27f"
    }
  }
]